Craniosynostosis, a condition where skull sutures fuse prematurely in children, can raise concerns about intracranial hypertension (ICH) – increased pressure within the skull. Traditionally, diagnosing ICH relies on invasive procedures. This review examines a promising new approach: handheld optical coherence tomography (OCT). Analyzing studies on handheld OCT use in children with craniosynostosis, we explore its feasibility, advantages, and potential role in improving diagnosis and patient care.
Craniosynostosis affects 1 in 2,000 newborns, often requiring surgery to correct skull shape and prevent complications. A significant concern is intracranial hypertension (ICH), which can damage the brain and vision if left untreated. Traditionally, diagnosing ICH involves invasive procedures like lumbar punctures or intracranial pressure monitoring. These methods are not ideal for young children, prompting the search for non-invasive alternatives.
Optical coherence tomography (OCT) is a revolutionary imaging technique that uses light to create detailed cross-sectional images of tissues. Recent advancements have led to the development of handheld OCT devices, making them more portable and user-friendly for pediatric applications. This review focuses on the feasibility of handheld OCT in diagnosing ICH in children with craniosynostosis.
Several studies have explored the use of handheld OCT in this context. These studies demonstrate promising results:
High Success Rates: Studies report successful image acquisition in a high percentage of children, exceeding 80% in some cases.
Feasibility for Young Children: Handheld OCT appears well-suited for young children, with good compliance and minimal discomfort.
Repeatability: Studies suggest good repeatability of OCT measurements, allowing for monitoring of pressure changes over time.
Handheld OCT offers several advantages over traditional methods for diagnosing ICH in children with craniosynostosis:
Non-invasive: Eliminates the need for needles or sedation, reducing risks and discomfort for children.
Quick and painless: OCT scans are completed in seconds, minimizing stress for patients.
Portable: Handheld devices allow for examinations at the bedside, improving accessibility.
Objective data: OCT provides quantitative measurements, aiding in diagnosis and monitoring.
While these initial studies are encouraging, further research is needed to fully establish handheld OCT as a standard diagnostic tool for ICH in children with craniosynostosis. Larger, multicenter trials are crucial to confirm its effectiveness and identify potential limitations. Additionally, exploring the correlation between OCT findings and other measures of ICH is important.
Handheld OCT holds immense potential for revolutionizing the diagnosis of ICH in children with craniosynostosis. This review highlights the feasibility, advantages, and future directions for this promising non-invasive technology. As research progresses, handheld OCT may become a valuable tool in improving early detection and management of ICH, leading to better outcomes for young patients.
1.
Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma
2.
According to new studies, some cancer patients can safely forego radiation therapy.
3.
According to a study, male testicular cancer risk is linked to neurodevelopmental disorders.
4.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
5.
Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk
1.
Unlocking the Secrets of Hemoglobin: How It Works to Keep Us Healthy
2.
Studying Lactic Acid in Pediatric Tumor Microenvironments: Experimental Approaches Explored
3.
Community-Based Cancer Survivorship Support Systems
4.
Omitting Axillary Dissection in Node-Positive Breast Cancer: Insights from the SENOMAC Trial
5.
Early Diagnosis of Lung Cancer Through Emerging Biomarkers
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
3.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
4.
Navigating the Complexities of Ph Negative ALL - Part III
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation